{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-25-000192","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.407478+00:00","generated_at":"2026-05-27T02:28:37.005576+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lexaria reduces at-the-market equity facility from $20M to $5M","bullets":["Amended Capital on Demand Sales Agreement with JonesTrading; maximum aggregate principal amount reduced to $5M from $20M.","Shares sold under new registration statement on Form S-3 (333-284407), effective Jan 30, 2025.","Agent commission remains 3.0% of gross sales price; customary indemnification and expense reimbursement.","Offering terminates upon sale of all Shares or termination of agreement by either party."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-25-000192","json":"https://secwatch.observer/filing/0001640334-25-000192.json","markdown":"https://secwatch.observer/filing/0001640334-25-000192.md","text":"https://secwatch.observer/filing/0001640334-25-000192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033425000192/0001640334-25-000192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033425000192/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:28:37.005576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}